FDG-PET can distinguish inflamed from non-inflamed plaque in an animal model of atherosclerosis.
The presence of activated macrophages is an important predictor of atherosclerotic plaque rupture. In this study, our aim was to determine the accuracy of (18)F- fluorodeoxyglucose (FDG) microPET imaging for quantifying aortic wall macrophage content in a rabbit model of atherosclerosis. Rabbits were divided into a control group and two groups post aortic balloon injury: 6 months high-cholesterol diet (HC); and 3 months HC followed by 3 months low-cholesterol diet plus statin (LCS). In vivo and ex vivo microPET, ex vivo well counting and histological quantification of the atherosclerotic aortas were performed for all groups. Macrophage density was greater in the HC group than the LCS group (5.1 +/- 1.4% vs. 0.6 +/- 0.7%, P < 0.001) with a trend towards greater macrophage density in LCS compared to controls (P = 0.08). There was a strong correlation across all groups between macrophage density and standardized uptake value (SUV) derived from ex vivo microPET (r = 0.95, P < 0.001) and well counting (r = 0.96, P < 0.001). Ex vivo FDG SUV was significantly different between the three groups (P < 0.001). However, the correlation between in vivo microPET FDG SUV and macrophage density was insignificant (r = 0.16, P = 0.57) with no statistical differences in FDG SUV seen between the three groups. This study confirms that in an animal model of inflamed and non-inflamed atherosclerosis, significant differences in FDG SUV allow differentiation of highly inflamed atherosclerotic aortas from those stabilized by statin therapy and low cholesterol diet and controls.
Division of Cardiovascular Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.
John R
JR
Davies
David
D
Izquierdo-Garcia
James H F
JH
Rudd
Nichola
N
Figg
Hugh K
HK
Richards
Joseph L E
JL
Bird
Franklin I
FI
Aigbirhio
Anthony P
AP
Davenport
Peter L
PL
Weissberg
Tim D
TD
Fryer
Elizabeth A
EA
Warburton
D000818:Animals; D001011:Aorta / Q000000981:diagnostic imaging* / Q000187:drug effects; D050197:Atherosclerosis / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000209:etiology; D000069059:Atorvastatin; D002404:Catheterization; D002791:Cholesterol, Dietary; D003937:Diagnosis, Differential; D004195:Disease Models, Animal; D019788:Fluorodeoxyglucose F18; D006538:Heptanoic Acids / Q000494:pharmacology; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology; D007249:Inflammation / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000209:etiology; D008264:Macrophages / Q000000981:diagnostic imaging; D008297:Male; D049268:Positron-Emission Tomography; D011237:Predictive Value of Tests; D011758:Pyrroles / Q000494:pharmacology; D011817:Rabbits; D019275:Radiopharmaceuticals
D002791:Cholesterol, Dietary; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; D000069059:Atorvastatin